Alzheimer's Treatment Takes a New Turn: Single Drugs Not Enough

Researchers are moving away from drugs that target one problem in Alzheimer's disease. Instead, they're testing medicines that attack multiple causes at once—much like how HIV treatment evolved. Early approved drugs slowed cognitive decline by 29% but didn't stop it, showing that clearing amyloid buildup alone isn't sufficient. Scientists now pursue targets including tau tangles, brain inflammation, and nerve damage simultaneously.